The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent non-metastatic prostate cancer,” published in the November 2024 issue of Urology by Dahmani et al.
Researchers conducted a retrospective study to evaluate if 11-oxygenated androgens, like 11-ketotestosterone (11KT), predict the onset of castration-resistant prostate cancer (CRPC). They found that high 11KT levels were linked to faster progression to CRPC.
They used mass spectrometry to quantify 11-oxygenated androgens in post-operative plasma from 145 patients with biochemical recurrence (BCR) treated with androgen deprivation therapy (ADT) and achieved castrated testosterone (T) levels. They performed Kaplan-Meier survival analysis and multivariable Cox models to assess the link between steroid levels and CRPC.
The results showed that 31 of 145 patients developed CRPC with a median time of 57 months. 11KT was the most abundant androgen and remained stable under ADT, unlike T and other steroids. Levels above 273 pg/mL were linked to a shorter time to CRPC (P=0.03), with a hazard ratio of 2.17 (95% CI 0.99-4.71; P=0.05).
They found that 11KT played a crucial role in predicting earlier CRPC onset. They suggested that understanding 11KT’s impact could improve hormonal therapy for castration-sensitive and patients with CRPC.
Source: auajournals.org/doi/10.1097/JU.0000000000004333
The post Impact of 11-Ketotestosterone on Progression in Patients With CRPC first appeared on Physician's Weekly.